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The role of chemokines and chemokine 
receptors in the pathogenicity of HIV 
These dramatic figures have prompted intensive research to define 
the bacterial and host factors involved in the septic response. Scien- 
tists from many disciplines, including chemistry, physic\, biology, 
medical microbiology, genetics, immunology, and pharmacolog, 
have worked closely with clinicians to achieve rapid arid profound 
progress. To translate this newly acquired knowledge into clinical 
practice, clinical trials have also been performed to evaluate numerous 
new therapeutic drugs. The disappointing results of these trials have 
underscored a major lesson, namely, that sepsis constitutes an 
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Combination chemotherapy targeting HIV-1 enzymes has led to 
major advances in the therapy of AIDS. This in turn has driven a 
scientific emphasis on  the development ofan HIV preveiitive vaccine. 
Though an appropriate goal, it cannot be done at the expense of 
developing new and better forms of therapy, since the current therapy 
is not adequate for several reasons, not the least of which are thc 
difficulties in compliance for all recipients and the economic and 
logistic virtual impossibility of the curreiit therapeutic approaches 
extremely complex syndrome and that basic and cliiiical research 
must be greatly intensified in order to illuminate the molecular 
mechanisms involved. 
The  recent development of innovative approaches for the treat- 
ment of sepsic juctify optimicni that the era of high mortality of septic 
patients inay find its end in the not too distant futurc. 
- .. 
Increasing resistance in Gram-positive 
pathogens 
reading the Third World. I believe that alternative and more bio- 
logical forms of therapy will be offsprings of basic research on  HIV 
biology and its mechanisms of disease induction. I will summarize 
efforts of our group, our collaborators, aiid in some instances of I .  
The problem of MRSA and vancomycin- 
resistant staphylococci 
others concerning two separate topics relevant to this point. 
1. Results of beta-chemokine block of HIV-1 infection, including 
results of G. Lewis, A. DeVico, and J. Burns in our institute (IHV) 
on  HIV-glycosaminoglycan interactions, its augmentation of anti- 
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HIV effects, and implications for therapy will be discussed as well as 
correlative results of A. Garzino-Demo, E Cocchi, and A. DeVico Staphylococci are the most frequently isolated bacteria in nosocoimal 
of IHV on  cheniokinr production and the clinical outcome in HIV- infections. A special property is their remarkable propensity to 
1-infected persons. acquire resistance to antibiotics either by plasmid-mediated gene 
2. HIV-I immune pathogenesis is not simply infection of CD4 T- transfer or by integration ofmobile genetic elements into the chronio- 
cells followed by cell death. Abundant evidence indicates that iridirect some. Today the term MRSA/E, which originally meant 
effects from viral proteins and cytohnes are likely equally or morc iiiethicillin-resistant Staplrylococcrds auretrc/epidermidis, usually indicates 
important. Rased on  detailed studies of the impaired proliferation of niultiresistance against almost all clinically available antibiotics, with 
uninfected T-cells In collaboration with D. Zdgury (who pioneered the exception of the glycopeptide-type antibiotics such as vanco- 
these approaches) and with others, we have concluded that the HIV- I myciii. Following the emergence of vancomycin-resistant entero- 
Tat protein and interferon-alpha are key determinants of this cocci and after the demonstration of the transfer of uanA resistance 
imniunosupprcssion. These results and clinical trials aimed a t  determinants under laboratory conditions, there is great fear that this 
reducing the amounts of these immunosuppressive proteins will be might also happen in the clinics. Indeed, isolation of vanconiycin- 
described. resistant S. aurrws ctrains called VKSA or  VISA has been recrntly 
described in Japan by Hiramatsu and coworkers, and subsequently 
also in the USA and some European countries. It has also been 
demonstrated that so-called heterogeneously resistant strains, which 
are difficult to detect by standard procedures and may serve as a 
precursor to homogeneously resistant VRSA, appear to be relatively 
widespread in many countries. However. the resistance mechanism(s) 
involved are differmt froin those seen in enterococci and appear to 
involve trapping ofvancomycin in the cell wall fabric and, by that, 
preventing the drug reaching its target (lipid I1 cell wall precursors). 
Epidemiology, mechanism(s) of resistance and some new therapeutic 
approaches to combat MRSAIVRSA will be discussed. 
New insights into sepsis and septic shock 
wl New insights into the pathogenesis and 
therapy of sepsis and septic shock 
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wl Molecular mechanisms of resistance in Severe sepsis and septic shock are the most serious complications of 
bacterial infections. Both Gram-positive aiid Grain-negative bacteria 
can trigger these extreme inflammatory responses and, by so doing, 
Gram-positive pathogens 
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Antibiotic therapy for infectious diseases exerts a sudden and strong 
selective pressure against pathogenic bacteria, as well as against the 
cause substantial morbidity and mortality. In the USA alone, over 
400 000 patients suffer from septicemia each year, and approximately 
100 000 of these patients die despite optimal intensive care and 
modern antimicrobial therapy. 
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